R&D FDA’s emerging framework to reduce animal testing: Implicati... Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.
R&D Bringing therapies to patients quicker with integrated CDMO ... Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.
R&D Sponsored Unlocking the future of obesity treatment Obesity is more than a number on the scale, it’s a complex, malignant disease linked to diabetes, cardiovascular conditions, and even certain cancers.
R&D GLP-1s in CKD: Evidence, market leadership, and key insights... At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight.
R&D Harnessing the cell's own degradation machinery, with Benedi... Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
R&D Future glances: More change, more tech, more harmonisation According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
